| Not Yet Recruiting | SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinom NCT06822010 | Rutgers, The State University of New Jersey | Phase 2 |
| Recruiting | DK222 Study at Hopkins NCT07140315 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Recruiting | Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothel NCT07421700 | Pfizer | Phase 1 / Phase 2 |
| Withdrawn | N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer NCT07217496 | Vadim S Koshkin | Phase 1 |
| Not Yet Recruiting | International Multicentric Retrospective Study on the Use of EV+P as First-line Therapy in Patients With la/mU NCT07420855 | Aron Research Foundation Ets | — |
| Not Yet Recruiting | A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder Cancer NCT07386847 | Pfizer | — |
| Recruiting | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer NCT07227168 | Sutro Biopharma, Inc. | Phase 1 |
| Recruiting | BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or NCT07193511 | Avenzo Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer Wit NCT07106762 | Bristol-Myers Squibb | Phase 2 / Phase 3 |
| Recruiting | Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin NCT07129993 | Daiichi Sankyo | Phase 2 / Phase 3 |
| Recruiting | SLV-154 Treatment of Metastatic Solid Tumors NCT06771219 | Solve Therapeutics | Phase 1 |
| Recruiting | Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as First Line Treatment for M NCT06657157 | Comprehensive Cancer Center Munich (CCCM) | — |
| Completed | Evaluation of Clinical Outcomes, Tolerability, and Costs of Avelumab Maintenance and Pembrolizumab Second-Line NCT07207928 | Azienda Ospedaliera Universitaria Integrata Verona | — |
| Terminated | A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combi NCT06448364 | Pfizer | Phase 1 |
| Recruiting | A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection NCT06011954 | Astellas Pharma Korea, Inc. | — |
| Active Not Recruiting | A Study of ADRX-0706 in Select Advanced Solid Tumors NCT06036121 | Adcentrx Therapeutics | Phase 1 |
| Active Not Recruiting | A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) i NCT05645692 | Hoffmann-La Roche | Phase 2 |
| Recruiting | A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies NCT04923178 | National Cancer Institute (NCI) | — |
| Recruiting | Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tu NCT05489211 | AstraZeneca | Phase 2 |
| Active Not Recruiting | Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer NCT05219435 | Spanish Oncology Genito-Urinary Group | Phase 2 |
| Completed | A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Ch NCT05366725 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | — |
| Terminated | Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors NCT05126433 | Jazz Pharmaceuticals | Phase 2 |
| Terminated | PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors NCT05233436 | Pfizer | Phase 1 |
| Completed | Pilot Trial of Colchicine in Urothelial Cancer and Other Solid Tumors NCT05279690 | Icahn School of Medicine at Mount Sinai | Phase 1 |
| Completed | Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) NCT05259696 | Palleon Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are NCT05059522 | Pfizer | Phase 3 |
| Terminated | Study of INCB086550 in Select Solid Tumors NCT04629339 | Incyte Corporation | Phase 2 |
| Recruiting | Sacituzumab Govitecan Plus EV in Metastatic UC NCT04724018 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Terminated | A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothel NCT04501094 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies NCT04114136 | Dan Zandberg | Phase 2 |
| Recruiting | Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) NCT04235777 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Safety and Efficacy of Pemigatinib in Patients With High-risk Urothelial Cancer After Radical Surgery NCT04294277 | European Association of Urology Research Foundation | Phase 2 |
| Completed | Efficacy and Safety of VasoClip® vs. WeckClip® for Robotic Urologic Surgery NCT07413120 | Incheon St.Mary's Hospital | Phase 3 |
| Active Not Recruiting | Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothe NCT04223856 | Astellas Pharma Global Development, Inc. | Phase 3 |
| Terminated | Stereotactic Ablative Radiation for Oligo-Progression of Urothelial Cancer NCT04131634 | University of Texas Southwestern Medical Center | Phase 2 |
| Terminated | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. NCT04152018 | Pfizer | Phase 1 |
| Active Not Recruiting | Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression NCT04180371 | BicycleTx Limited | Phase 1 / Phase 2 |
| Completed | Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA) NCT03425201 | Fundacion CRIS de Investigación para Vencer el Cáncer | Phase 1 / Phase 2 |
| Active Not Recruiting | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid T NCT03983954 | NeoTX Therapeutics Ltd. | Phase 1 |
| Active Not Recruiting | ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With M NCT04044859 | USWM CT, LLC | Phase 1 |
| Completed | A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations NCT03955913 | Janssen Research & Development, LLC | — |
| Completed | A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Ad NCT03474107 | Astellas Pharma Global Development, Inc. | Phase 3 |
| Completed | Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Uro NCT03406650 | Swiss Cancer Institute | Phase 2 |
| Terminated | A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (J NCT03472560 | Pfizer | Phase 2 |
| Terminated | GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors NCT03576131 | Genmab | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Ur NCT03390504 | Janssen Research & Development, LLC | Phase 3 |
| Terminated | Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents NCT03317496 | Pfizer | Phase 1 / Phase 2 |
| Terminated | A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer NCT03288545 | Astellas Pharma Global Development, Inc. | Phase 1 / Phase 2 |
| Completed | A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer NCT03219333 | Astellas Pharma Inc | Phase 2 |
| Terminated | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma NCT03207867 | Novartis Pharmaceuticals | Phase 2 |
| Active Not Recruiting | Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of NCT03036098 | Bristol-Myers Squibb | Phase 3 |
| Withdrawn | A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumo NCT02661100 | Case Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Terminated | Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 NCT02891161 | Monika Joshi, MD | Phase 1 / Phase 2 |
| Withdrawn | RADVAX™: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial NCT02880345 | Abramson Cancer Center at Penn Medicine | Phase 1 |
| Completed | Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung NCT02769962 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100) NCT02603432 | Pfizer | Phase 3 |
| Recruiting | Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue NCT02379429 | National Cancer Institute (NCI) | — |
| Active Not Recruiting | Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial NCT02516241 | AstraZeneca | Phase 3 |
| Active Not Recruiting | An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer NCT02365597 | Janssen Research & Development, LLC | Phase 2 |
| Terminated | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) NCT02393248 | Incyte Corporation | Phase 1 / Phase 2 |
| Completed | Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052) NCT02335424 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced NCT02256436 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | A Study of TAS-120 in Patients With Advanced Solid Tumors NCT02052778 | Taiho Oncology, Inc. | Phase 1 / Phase 2 |
| Completed | Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen NCT02033993 | Canadian Cancer Trials Group | Phase 2 |
| Completed | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positiv NCT02111850 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Withdrawn | Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer NCT01700010 | University of Michigan Rogel Cancer Center | Phase 2 |
| Terminated | Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC) NCT01663285 | University of Michigan Rogel Cancer Center | Phase 2 |
| Completed | The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothel NCT01801137 | Hopital Foch | Phase 2 |
| Completed | Phase II Study of TKI258 in Advanced Urothelial Carcinoma NCT00790426 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Genetic Determinants of Response to Neoadjuvant Cisplatin-based Chemotherapy in Urothelial Cancer NCT01206426 | University of Chicago | — |
| Terminated | Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Can NCT00995488 | University of Michigan Rogel Cancer Center | Phase 2 |
| Active Not Recruiting | A Genotype-Phenotype Urothelial Cancer Registry NCT00902590 | Memorial Sloan Kettering Cancer Center | — |
| Completed | Gemzar, Cisp, Sunitinib Urothelial Ca NCT00821327 | US Oncology Research | Phase 2 |
| Completed | SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial NCT00578526 | AHS Cancer Control Alberta | Phase 2 |
| Recruiting | Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer NCT00872495 | Lahey Clinic | — |